If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 10 of 30

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Subjects with KRAS G12C Mutant Advanced Solid Tumors

Objective
This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Protocol No
MERCK-MK1084-001
Categories
Cancer, Kidney, Other Skin, Thoracic Cancers, Sarcoma, Gastrointestinal Cancers, Cervix, Prostate and Urologic Cancers, Other Gynecologic, Breast Cancers, Ovary, Gynecologic Cancers, Head and Neck Cancers, Early Phase/Multiple Disease Site Cancers, Endocrine Cancers, Melanoma, Skin, Eye/Orbital Cancers, Skin Cancers

An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses

Objective
IIT-GEORGE-I-PREDICT
Protocol No
IIT-GEORGE-I-PREDICT
Categories
Cancer, Colorectal, Gynecologic Cancers, Esophagus, Other Urologic, Head and Neck Cancers, Early Phase/Multiple Disease Site Cancers, Esophagus, Skin Cancers, Stomach, Prostate and Urologic Cancers, Pancreas/Liver, Breast Cancers, Other Gastrointestinal, Sarcoma, Gastrointestinal Cancers, Lung, Thoracic Cancers

REMASTer: REcurrent Brain Metastases After SRS Trial

Objective
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Protocol No
MONTERIS-CL10153-REMASTER
Categories
Cancer, Endocrine Cancers, Uterine, Other Urologic, Colorectal, Cervix, Lung, Brain and Spine Cancers, Prostate, Stomach, Skin Cancers, Prostate and Urologic Cancers, Other Respiratory, Gastrointestinal Cancers, Breast Cancers, Head and Neck Cancers, Esophagus, Ovary, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Gynecologic Cancers, Sarcoma, Eye/Orbital Cancers

A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors

Objective
A First-in-Human, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Protocol No
XILIO-XTX301-01-02-001
Categories
Cancer, Gynecologic Cancers, Thoracic Cancers, Colorectal, Early Phase/Multiple Disease Site Cancers, Kidney, Other Skin, Pancreas/Liver, Other Urologic, Prostate and Urologic Cancers, Stomach, Skin Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Sarcoma, Breast Cancers

A Phase 1/2, Open-Label, Multicenter, First-in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors

Objective
The purpose of this study is to learn more about an investigational drug called DS-3939a. DS-3939a is an investigational drug that is not approved for your disease. It is being studied to see if it is safe and if your disease or medical condition improves while taking it.
Protocol No
DAIICHI-SANKYO-DS3939-077
Categories
Cancer, Prostate and Urologic Cancers, Kidney, Skin Cancers, Stomach, Uterine, Head and Neck Cancers, Esophagus, Thoracic Cancers, Ovary, Other Gastrointestinal, Sarcoma, Gastrointestinal Cancers, Prostate, Cervix, Gynecologic Cancers, Early Phase/Multiple Disease Site Cancers, Breast Cancers

An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations

Objective
An Open-label, Multicenter Study of LY4050784 in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Protocol No
LOXO-J5M-OX-JOXA
Categories
Cancer, Stomach, Prostate, Breast Cancers, Other Skin, Lip, Oral Cavity and Pharynx, Larynx, Ovary, Head and Neck Cancers, Thoracic Cancers, Sarcoma, Other Urologic, Pancreas/Liver, Cervix, Gynecologic Cancers, Esophagus, Melanoma, Skin, Bladder, Gastrointestinal Cancers, Prostate and Urologic Cancers, Early Phase/Multiple Disease Site Cancers, Skin Cancers